Vanguard reports 5.19% stake in SELLAS Life Sciences
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 9,666,278 securities of SELLAS Life Sciences Group Inc, representing 5.19% of the common stock class identified by CUSIP 81642T209 as of June 30, 2026.
Rhea-AI Filing Summary
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 9,666,278 securities of SELLAS Life Sciences Group Inc, representing 5.19% of the common stock class identified by CUSIP 81642T209 as of June 30, 2026. Vanguard reports sole voting power over 1,400,173 securities and sole dispositive power over all 9,666,278 securities, with no shared voting or dispositive power. The position is held by Vanguard Capital Management LLC together with specified affiliates and business divisions, and consists of warrants, even though the CUSIP corresponds to the issuer’s ordinary shares. Vanguard notes that various Vanguard funds and managed accounts have the right to receive dividends or sale proceeds on these securities, but no other single person has an interest in more than 5% of the class.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
dispositive power financial
Schedule 13G regulatory
Investment Company Act of 1940 regulatory
warrants financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of SELLAS Life Sciences Group (SLS) does Vanguard Capital Management report owning?
How many SELLAS (SLS) securities does Vanguard Capital Management beneficially own?
Which Vanguard entities are included in the SELLAS (SLS) Schedule 13G filing?
Are Vanguard’s SELLAS (SLS) holdings on behalf of other investors?
What type of SELLAS (SLS) securities does Vanguard Capital Management hold?
AI-generated analysis. How Rhea-AI works. Not financial advice.